Month: July 2021

Posted on

UL collabore avec WIZZIT Digital pour faire progresser les paiements de détail en Afrique subsaharienne avec le lancement d’une solution de paiement mobile SoftPOS avec PIN

UL et WIZZIT Digital contribuent à accélérer le déploiement des paiements sans contact pour favoriser l’inclusion financière et permettre aux commerçants de toutes tailles de réaliser leurs ambitions.

JOHANNESBURG, le 31 juillet 2021 /PRNewswire/ — UL, le leader mondial des sciences de la sécurité, a annoncé que WIZZIT Digital, une société de paiements numériques, a lancé une solution logicielle de point de vente (SoftPOS) Tap2Pay avec prise en charge de la saisie du numéro d’identification personnel (PIN). Cette solution permet de transformer des appareils commerciaux (COTS) en terminaux de paiement de point de vente (POS). Tap2Pay est la première solution SoftPOS développée en Afrique du Sud qui prend en charge la saisie du code PIN et est reconnue par Visa et Mastercard. WIZZIT Digital est désormais opérationnel avec un premier client de lancement, l’une des plus grandes banques commerciales panafricaines.

UL has announced that WIZZIT Digital has launched a Tap2Pay software point-of-sale (SoftPOS) solution with personal identification number (PIN) entry support. This solution transforms commercial off-the-shelf (COTS) devices into point-of-sale (POS) payment terminals. Tap2Pay is the first SoftPOS solution developed in South Africa that supports PIN entry and is recognized by Visa and Mastercard. (PRNewsfoto/UL)

Pour surmonter les difficultés liées à la mise sur le marché d’une solution SoftPOS, UL a soutenu la solution Tap2Pay depuis son développement jusqu’à son entrée sur le marché. Dans un premier temps, UL a fourni des services de conseil pour aider WIZZIT Digital à s’orienter dans le paysage réglementaire des paiements et à répondre aux exigences des systèmes de paiement. Lorsque Tap2Pay a été prêt pour les tests fonctionnels, UL l’a testé avec une série d’outils accrédités par le système afin de fournir un retour sur les problèmes potentiels. Après le débogage et le dépannage, UL a fourni des services de tests fonctionnels et a aidé WIZZIT Digital à obtenir l’approbation du type pilote Visa. Après l’approbation fonctionnelle, les laboratoires de sécurité d’UL ont évalué la solution pour les programmes pilotes de sécurité de Mastercard et de Visa. Ces tests et évaluations par rapport aux exigences du projet ont permis à WIZZIT de mettre la solution sur le marché.

L’évaluation d’UL a confirmé que la solution Tap2Pay répondait aux principales exigences de sécurité avant d’entrer sur le marché. Il s’agissait notamment d’aider à affirmer la sécurité des données de paiement obtenues par une interface de communication en champ proche (NFC) et un noyau sans contact du dispositif COTS. Les mécanismes de sécurité, les contrôles et les mesures d’atténuation de la solution protègent les données du compte du consommateur et d’autres actifs.

Tap2Pay entre sur le marché à un moment où la demande de solutions de paiement sans contact augmente. Selon Deloitte, la pandémie de COVID-19 a rendu le besoin de numérisation des paiements plus critique que jamais. Cependant, de nombreux marchés émergents sont confrontés à des problèmes d’acceptation des cartes. Deloitte a également noté qu’en Afrique du Sud, environ 90 % des 100 000 magasins du secteur informel n’acceptent que des espèces. Pour répondre à la demande des clients et accroître l’acceptation des cartes par le marché des petites entreprises, y compris les commerçants des zones rurales, il faut une solution abordable.

UL Logo (PRNewsFoto/UL) (PRNewsFoto/UL)

Jako Fritz, conseiller principal en matière de sécurité chez UL, a déclaré : « SoftPOS est une approche entièrement nouvelle des paiements numériques qui réduit la barrière d’entrée pour les commerçants afin d’accepter les transactions par carte sans contact. L’informatique cloud, ainsi que le protocole Europay, MasterCard et Visa, permettent de passer du traditionnel point de vente physiquement sécurisé au traitement des transactions par logiciel COTS. Ces solutions aideront les propriétaires de micro-entreprises et de petites entreprises ainsi que les commerçants du monde entier à répondre aux exigences d’une société de plus en plus dépourvue de numéraire, de manière plus sûre et avec un investissement minimal. »

Expliquant comment Tap2Pay répond à un besoin non satisfait du marché, Brian Richardson, PDG et cofondateur de WIZZIT Digital, a déclaré : « Depuis près de deux décennies, nous travaillons avec des banques et des institutions financières sur les marchés émergents, y compris de nombreux pays d’frique. Notre expérience nous a appris deux choses. Tout d’abord, les consommateurs et les banques veulent la protection d’un code PIN lorsqu’ils effectuent des transactions sans contact. Dans un contexte de cyberfraude croissante, le code PIN offre un niveau de sécurité universellement accepté et auquel les gens font confiance. Deuxièmement, les solutions traditionnelles de paiement sans espèces sont trop coûteuses pour les micro et petits commerçants.

« Pour les petits commerçants, l’investissement initial dans les terminaux et les coûts de maintenance permanents sont tout simplement trop élevés. Tap2Pay SoftPos with PIN supprime cette barrière, permettant aux commerçants de toute taille d’accepter les paiements sans espèces. Cela leur permettra en fin de compte d’attirer davantage de clients, y compris ceux qui ne veulent pas payer en liquide des biens et des services, pour une fraction du coût », a déclaré M. Richardson.

À propos d’UL
UL est le leader mondial des sciences de la sécurité. Nous fournissons des services de test, d’inspection et de certification (TIC), de formation et de conseil, des solutions de gestion des risques et des informations commerciales essentielles pour aider nos clients, basés dans plus de 100 pays, à atteindre leurs objectifs de sécurité et de durabilité. Notre connaissance approfondie des produits et notre intelligence des chaînes d’approvisionnement font de nous le partenaire de choix des clients confrontés à des défis complexes. Découvrez-en davantage sur UL.com.

Pour en savoir plus sur le développement des normes et les autres activités à but non lucratif, visitez le site UL.org.

Contacts avec la presse :
Steven Brewster
UL
ULNews@UL.com
+1.847.664.8425

Christina Bostock
IHC
christina@ih-c.com
971.55.887.3054

Photo – https://mma.prnewswire.com/media/1578854/UL_Wizzit.jpg
Logo – https://mma.prnewswire.com/media/325015/ul_enterprise_logo.jpg

Posted on

International Aid Cuts Could Affect Millions Across Africa

KAYA, BURKINA FASO - The COVID-19 pandemic has led to cuts in foreign aid from donor nations such as Britain, which this month slashed its aid budget by $5.5 billion. The funding loss is being felt in Burkina Faso, where it could shut down a group that helps thousands of survivors of gender-based violence and rape.

Britain has cut its annual aid budget, and so have other countries, such as Australia, Japan and Saudi Arabia.

The largest international nonprofits say the shockwaves of the cuts will be felt by people across Africa in all kinds of situations and will result in deaths.

“For countries like the U.K. and others to be cutting their aid budgets in a global pandemic is extremely shortsighted, and we know it will put the fight back against poverty by many decades. So, the U.N. secretary general, for example, has called these cuts a death sentence, and it really is that stark for many people,” said Sam Nadel, Oxfam government relations chief.

MSI Reproductive Choices, a group offering family planning to countries in crisis, such as Burkina Faso, where over 1.3 million people have been displaced by conflict, is primarily supported by British aid money.

The cuts will affect large numbers of women, says the head of MSI-Burkina Faso, Dr. Toumbi Sissoko.

Overall, MSI has been able to assist more than 500,000 beneficiaries over two years, she says. She points to Burkina Faso’s context of insecurity, which she says makes women even more vulnerable.

“Alice,” whose name has been changed to protect her identity, received help from MSI after she fled her village in northern Burkina Faso when gunmen attacked. She trekked through the bush for three days, seeking refuge, but then was seized by a group of terrorists.

Alice says they told her to put her daughter down before one of them hit her with the butt of his gun, knocking her to the ground. Six of them raped her, then discussed whether they should kill her but, she says, they concluded it was useless to kill a woman. They got on their motorbikes and left.

When she reached the relative safety of Kaya the next day, she was directed to MSI-Burkina Faso.

Alice OK? says a woman from MSI immediately gave her morning-after pills and advice. She was still traumatized and could neither eat nor breast-feed her daughter. She said that the woman at MSI encouraged her to eat and told her that her life was still worth living.

Flora Guibere works for MSI. She thinks that with the aid cuts, beneficiaries will be left on their own, and the funding to support them won’t exist, and many of her organization’s workers will be out of a job.

For women who fall victim to gang rape, like Alice,OK? it will mean they may no longer receive emergency birth control or support.

Source: Voice of America

Posted on

At 46, African Skateboarder Finally Wows Mom at Tokyo Games

TOKYO - At age 46, the second-oldest skateboarder at the Tokyo Games is hoping to not have a heart attack and have mounds of fun. Should be no problem. Fun has been a life's work for Dallas Oberholzer.

"I have never had a real job. I have never applied for a job," he says. "My whole life has just been skateboarding. I am just hooked."

Skateboarding's young guns, with their endorsements and boards bearing their names, have bigger tricks and bigger Instagram followings than the grizzled South African with a salt-and-pepper beard. Oberholzer isn't expecting to beat them when they go wheel-to-wheel this week in Tokyo's huge purpose-built Olympic skate bowl.

But Oberholzer has big tales, woven from a nomadic existence on four squeaky polyurethane wheels. If skateboarding is the punk rock sport of the Games, disruptive and not taking itself too seriously, then Oberholzer is its Iggy Pop — raw, wild and worn, someone who can talk and talk and talk.

About, say, when he worked as a concert chauffeur, ferrying around Janet Jackson's dancers. Or his 16-month road trip, from Canada all the way to Argentina, after he graduated from university with a degree in marketing that he quickly realized he had no use for.

"Just a collection of experiences" is how he describes himself. Another description could be: A mascot for middle-aged people everywhere, flying the flag for Generation X against Gens Y and Z.

"I'm not going to win. I am not going to get a medal," he said. "But, like, I am legitimately the best guy in Africa. By default, the best guy in Africa goes to the Olympics."

"It's just unbelievably epic," he added. "It's all expenses paid and it's going to be the best course I would have ever skated in my life."

Only Rune Glifberg, aka "the Danish Destroyer" and also 46, is older (by eight months) than Oberholzer among the 80 men and women competing in skateboarding's Olympic debut in Tokyo.

In the men's park competition on Thursday, Oberholzer and Glifberg — with their spiky shocks of grey-flecked hair — will face skaters less than half their age.

The women's event on Wednesday has even younger skaters: Kokona Hiraki of Japan is just 12. In the women's street event in Week 1, three young teens — 13, 13 and 16 — won gold, silver and bronze.

"I have got nothing to lose, nothing to prove. I know I am 46 and all I need to do is keep my cardio up so I can stay on my skateboard for 45 seconds," Oberholzer said. "I'm going to be the one smiling, bro. I hope. Or I will be having a mild heart attack."

Skating's age range is remarkably broad for an Olympic event and testifies to the sport's inclusivity. In July, skating pioneer Tony Hawk competed at the X Games at age 53, and was beaten by a 12-year-old, Gui Khury.

The sport's coffee mug could read: "Skaters don't grow old, they just get new wheels."

"Skateboarding definitely makes you feel younger," Glifberg said. "It's not just a physical thing. It's a lot to do with style and grace and just the way that you present yourself on the board."

Whereas Gens Y and Z have had "how-to" videos on YouTube and Instagram to teach them tricks, Oberholzer and Glifberg had to find their own way.

Glifberg started right around the time that Back to the Future turned kids onto skating in 1985. For Oberholzer, it was a rented VHS copy of the 1986 movie Thrashin’, about skateboarding gangs, that "made all our eyeballs pop out."

Until then, his sport had been tennis.

"I remember just thinking to myself, 'I could play tennis and let the ball have all the fun or I could be the ball,'" he recalled. "And I'm like, 'I want to be the ball. I want to be the one flying around.'"

Anti-apartheid leader Nelson Mandela was still in prison when Oberholzer started riding buses into central Johannesburg in search of places to skate. Schooled, like other white South Africans, separately from Black kids, it was on his board that Oberholzer first started to meet and mingle with Black peers who also skated.

"It really helped me get over my apartheid upbringing," he said.

In turn, Oberholzer is giving back. He uses skateboarding to reach out to kids in tough neighborhoods, to keep them from drugs and gangs and help them develop skills. The Indigo Youth Movement he founded has built multiple skate parks and ramps.

But none of that has impressed his mum, Linda, quite like qualifying for the Olympics.

"My mom is finally happy with my life choices, bro. You know what a good feeling that is? It's taken that long for my mom to acknowledge what I do with my life," he said. "That's probably the best thing I'm taking out of this, is that my mom finally goes, 'Wow.'"

Source: Voice of America

Posted on

COVID Infections Reach Record High in Tokyo

Tokyo’s metropolitan government said new coronavirus infections surged to a record high Saturday as the city hosts the Olympic Games.

The government reported 4,058 new cases, topping 4,000 for the first time.

The new record was set one day after Japan extended a state of emergency for Tokyo through the end of August to contain the spread. The extension also applies to three prefectures near Tokyo and the western prefecture of Osaka.

A new record for infections also was set nationwide Saturday. Public broadcaster NKH reported 12,341 new cases, 15% higher than the day before.

“The pandemic will end when the world chooses to end it,” World Health Organization Director-General Dr Tedros Adhanom Ghebreyesus said Friday in Geneva about the global COVID-19 outbreak that is now being driven by the delta variant of the coronavirus. The U.S. Centers for Disease Control and Prevention says the delta variant is as contagious as chicken pox and that infections in vaccinated people may be as transmissible as those in the unvaccinated.

“WHO’s goal remains to support every country to vaccinate at least 10% of its population by the end of September, at least 40% by the end of this year, and 70% by the middle of next year,” the WHO chief said, but added that the realization of the goals is “a long way off.”

“So far, just over half of countries have fully vaccinated 10% of their population, less than a quarter of countries have vaccinated 40%, and only three countries have vaccinated 70%,” Tedros said.

He recalled that WHO had earlier “warned of the risk that the world’s poor would be trampled in the stampede for vaccines” and that “the world was on the verge of a catastrophic moral failure” because of vaccine inequity.

“And yet the global distribution of vaccines remains unjust,” Tedros said. “All regions are at risk, but none more so than Africa.”

“Many African countries have prepared well to roll out vaccines, but the vaccines have not arrived,” he said. “Less than 2% of all doses administered globally have been in Africa,” with only 1.5% of the continent’s population fully vaccinated.

The WHO chief said his organization was “issuing an urgent call” for $7.7 billion for the launching of the Rapid ACT-Accelerator Delta Response, or RADAR, a response to the delta surge that would provide tests, treatments and vaccines.

He also said COVAX; which provides vaccines to lower-income countries, needs additional funding.

“The question is not whether the world can afford to make these investments,” Tedros said,” it’s whether it can afford not to.”

U.S. President Joe Biden announced Thursday that civilian federal government employees must be vaccinated or submit to regular testing and wear masks.

On Friday, a reporter asked Biden as he was leaving the White House whether Americans should expect more guidelines and restrictions related to the coronavirus. “In all probability,” he said.

Biden also noted that on Thursday almost a million Americans received COVID-19 vaccinations and said, “I am hopeful that people are beginning to realize how essential it is to move” in response to the coronavirus threat.

The White House said the average number of people getting their first shot of the coronavirus vaccines this week was up 30% over last week.

Also Friday, Walmart joined a growing number of U.S. companies issuing mandates for its workers to be vaccinated, saying the policy would apply to all employees at its headquarters along with managers who travel within the United States.

The Broadway League said Friday that audiences will be required to show proof of vaccination to watch Broadway performances and will be required to wear masks.

Vietnam said Saturday it would extend travel restrictions in Ho Chi Minh City and 18 other southern cities and provinces for another two weeks to contain its worst outbreak to date, according to Reuters.

The extension begins Monday in a country that contained the virus for much of the pandemic but reports a total of 145,000 cases and more than 1,300 deaths, 85% of which were reported in the last month.

A weekend lockdown has been imposed in India’s southern state of Kerala as it grapples with some 20,000 new cases daily, Reuters reported. Federal authorities sent experts to the area to monitor developments in the state that accounts for more than 37% of the nearly 32 million cases reported by India’s health ministry.

Australia's third-largest city of Brisbane said it would begin a COVID lockdown on Saturday amid rising case numbers. Neighboring areas will also be subject to the stay-at-home orders.

Australian Prime Minister Scott Morrison said Friday that 80% of adults must be vaccinated before the country will consider reopening its border.

In Israel, health officials began administering coronavirus booster shots Friday to people older than 60 who have been fully vaccinated in an effort to stop a recent spike in cases.

Italy’s Health Institute announced Friday that the delta variant accounted for almost all new COVID-19 cases in the country at nearly 95% of cases as of July 20.

German officials announced Friday that unvaccinated travelers arriving in the country will need to present a negative COVID-19 test result.

The Johns Hopkins Coronavirus Resource Center Saturday reported there have been more than 197 million global COVID infections.

Source: Voice of America

Posted on

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines

Dubai, United Arab Emirates, July 30, 2021 (GLOBE NEWSWIRE) — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development and commercialization rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide outside of Japan. Takeda will retain commercialization rights in Japan and HilleVax will integrate certain Japan development activities into its global development. Takeda remains committed to vaccines and this collaboration allows Takeda to focus primarily on dengue, COVID-19, pandemic influenza and Zika.

HIL-214, which is a virus-like particle (VLP) based vaccine candidate, completed a randomized, placebo-controlled Phase 2b field efficacy study in 4,712 adult subjects in which HIL-214 was well-tolerated and demonstrated clinical proof of concept in preventing moderate-to-severe cases of acute gastroenteritis from norovirus infection.1 To date, the candidate has been studied in nine human clinical trials with safety data from over 4,500 subjects and immunogenicity data from over 2,000 subjects.

Ursula Belinda Myles, General Manager of Takeda’s Access Market Cluster (covering much of Africa) commented: “Africa’s underlying burden of endemic diseases is one of the largest in the world, and infectious diseases play a larger portion of these diseases across the continent. Like many other nations, COVID-19 has emphasized Africa’s greatest challenges around healthcare and highlighted the need for continued greater investment in healthcare systems. These investments are critical to secure economic development as Africa implements flagship projects around the 2030 Africa Health Strategy.”

Ursula added: “The announcement of our partnership with Frazier Healthcare Partners will allow Takeda to focus efforts and resources on vaccines for diseases prevalent across Africa and provide support in alleviating the growing burden that infectious diseases have on public health systems.”

Norovirus is a common intestinal infection marked by diarrhea, vomiting, abdominal cramps, nausea and sometimes fever that may lead to clinically significant dehydration.2 Norovirus is recognized as the leading cause of acute gastroenteritis across the age spectrum.3 It is estimated that norovirus causes nearly 700 million cases of illness and more than 200,000 deaths worldwide per year with significant additional economic and social burden.3 No vaccines are currently approved for norovirus infection, and HIL-214 continues to be the most advanced norovirus vaccine candidate in human clinical trials.

“Takeda and Frazier have a history of successfully partnering together, and we are confident in HilleVax’s capabilities to progress HIL-214, the most advanced norovirus vaccine candidate in development with the potential to address the huge global burden of norovirus-associated acute gastroenteritis,” said Rajeev Venkayya, M.D., President of the Global Vaccine Business Unit, Takeda. “This will allow Takeda to focus its efforts and resources on our dengue vaccine, which we have begun filing for licensure around the world, our pandemic programs, and our partnership with the US Government to develop a Zika vaccine

 Takeda’s Commitment to Vaccines

Vaccines prevent 2 to 3 million deaths each year and have transformed global public health. For more than 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, COVID-19, pandemic influenza and Zika. Takeda’s team brings an outstanding track record and a wealth of knowledge in vaccine development and manufacturing to advance a pipeline of vaccines to address some of the world’s most pressing public health needs. For more information, visit www.TakedaVaccines.com.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

About Frazier Healthcare Partners

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe. For more information about Frazier Healthcare Partners, visit the company’s website at http://www.frazierhealthcare.com.

About HilleVax

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates.  Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.

Takeda Pharmaceutical Company Limited Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 CONTACTS:

Takeda Media Contacts:
Japanese Media

Ryoko Matsumoto

ryoko.matsumoto@takeda.com

+81 (0) 3-3278-3414

 edia Outside Japan

Amy Atwood

amy.atwood@takeda.com

+1-774-571-3316
For HilleVax, Inc.: For Frazier Healthcare Partners:
David Socks

info@hillevax.com

+1-650-325-5156

 Liz Park

liz.park@frazierhealthcare.com

+1-650-319-1831

References

1 Sherwood J, et al. Vaccine 2020; 38(41):6442-6449

2 https://ww.cdc.gov/norovirus/index.html [accessed 2021 April 27].

3 Hall AJ, et al. Expert Rev Vaccines 2016;15(8):949-951

Mohammed Al Nasseri
Takeda Pharmaceuticals
+971507694646
Mohammed.alnasseri@fleishman.com